A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
For Parts A \& B:
Body mass index (BMI) of 18 to 34 kg/m2, inclusive, and total body weight ≥ 50 kg
Documentation of normal Allen's test result at Screening and on PET scanning days in the arm that will be used for arterial line placement
For Part A only:
Healthy male and female participants without clinically significant deviation from normal in medical history, physical examination (PE), electrocardiograms (ECGs), and clinical laboratory determinations
For Part B only:
Male or female participant diagnosed with MS according to the 2017 revisions of the McDonald diagnostic criteria
Expanded Disability Status Scale (EDSS) score between 0 to 6.5, inclusive, at Screening
You may not be if
For Parts A \& B:
Benign MS defined as a baseline EDSS of 2.0 with MS diagnosis ≥ 10 years prior to Day 1. Spinal MS without clinical or radiological evidence of brain lesions. Any other combination of clinical and radiological data suggestive of an absence of inflammatory brain lesions.
Any major surgery within 4 weeks of study treatment administration and/or any minor surgery within 2 weeks of tracer administration
For Part A only:
Any significant acute or chronic medical illness
For Part B only:
Any significant acute or chronic medical illness (other than MS) posing a risk to the participant's safety or negatively affecting the ability to detect CNS PET signal
MS relapse within 14 days prior to Day 1. Participants with a MS relapse within 30 days prior to Day 1 must agree to have their second PET scan scheduled on Day 1 or Day 2
Clareo Health | A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis
